Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06459427
Other study ID # 01084205031
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2025
Est. completion date December 2027

Study information

Verified date June 2024
Source China-Japan Friendship Hospital
Contact Yanbing Yu, M.D.
Phone +86-13901114963
Email yuyanbing123@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are: - Establish a multi-center clinical database for brainstem hemorrhage. - Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits. - Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning. Participants in the experimental group will: - Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture - Receive conservative non-surgical treatment. If there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 110
Est. completion date December 2027
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Diagnosed with brainstem hemorrhage via imaging, with hematoma volume calculated to be greater than 3 mL using the Tada formula in conjunction with 3D Slicer software for three-dimensional reconstruction; - Glasgow Coma Scale (GCS) score of 3-8 at admission, with the patient in a comatose state but maintaining vital signs; - Detailed and complete clinical data; - Age between 18 and 70 years. Exclusion Criteria: - Suspected [unless excluded by angiography or Computed Tomography angiography (CTA)/Magnetic Resonance Angiography (MRA)/Magnetic Resonance Imaging (MRI)] or untreated ruptured cerebral aneurysm, Moyamoya disease, ruptured intracranial Arteriovenous Malformations (AVM), or tumor; - Patients with significant organ dysfunction; - Patients with brain herniation; - Patients with obstructive hydrocephalus; - Patients with coagulation disorders or unstable vital signs; - Patients with incomplete clinical data or surgical contraindications; - Patients who used dabigatran, apixaban, and/or rivaroxaban (or drugs of the same class) before symptom onset; Criteria for terminating the clinical trial: - Participants who are unwilling or unable to continue the trial. - Situations where the researcher deems it necessary to terminate the trial, such as discovering post-enrollment that a participant does not meet inclusion criteria or meets any exclusion criteria. - Occurrence of intolerable adverse events or serious adverse events, where the researcher judges that the risk to the participant of continuing the trial outweighs the benefits. - Loss to follow-up. (If a participant withdraws from the study due to adverse events, the researcher must take active measures to provide symptomatic treatment.) Dropout Criteria: Participants who have provided informed consent and passed screening to enter the trial but fail to complete the observation period specified in the protocol will be treated as dropouts. If a participant is lost to follow-up or fails to complete the assessment on time, the study coordinator must record this in the online registration system. A participant will be considered "lost to follow-up" if they cannot be contacted for 6 months. Every effort must be made to contact participants at each follow-up time point, even if they could not be reached at the previous time point. Loss to follow-up is unacceptable, and in such cases, the researchers at the study center must develop a remedial plan to improve participant tracking. All trial-related data for dropout cases should be properly preserved for both archival purposes and the necessary analysis. There is no need to replace dropout participants. Elimination Criteria: - Participants who were mistakenly enrolled. - Participants with no evaluable records after enrollment. - Participants who severely violate the trial protocol during the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Robot-Assisted Stereotactic Brainstem Hematoma Puncture
Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is <3 mL or if the drainage tube has been in place for >5 days, the drainage tube is removed.
Drug:
Conservative non-surgical treatment
Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).

Locations

Country Name City State
China Aerospace Center Hospital Beijing Beijing
China China-Japan Friendship Hospital Beijing Beijing
China Hebei Provincial People's Hospital Shijiazhuang Hebei

Sponsors (1)

Lead Sponsor Collaborator
Yanbing Yu

Country where clinical trial is conducted

China, 

References & Publications (1)

Lui TN, Fairholm DJ, Shu TF, Chang CN, Lee ST, Chen HR. Surgical treatment of spontaneous cerebellar hemorrhage. Surg Neurol. 1985 Jun;23(6):555-8. doi: 10.1016/0090-3019(85)90002-3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary survival rate Six-month survival rate after follow-up Six-month
Secondary The favorable prognosis rate for modified Rankin Scale (mRS) .(proportion of patients with mRS = 3) The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. This study calculates the proportion of individuals with an mRS score of = 3 at 6 months follow-up. six months
Secondary The favorable prognosis rate for Activities of Daily Living - Modified Barthel Index (ADL-MBI) .(proportion of patients with ADL-MBI = 3) The Activities of Daily Living (ADL) scale is used to assess a patient's ability to independently perform basic activities in daily life such as dressing, bathing, eating, and moving around. One of the most commonly used scales globally for evaluating ADL capacity is the Modified Barthel Index (MBI). The MBI scoring system is divided into 5 levels with scores as follows: (15, 12, 8, 3, 0; 10, 8, 5, 2, 0; 5, 4, 3, 1, 0). Different levels represent varying degrees of independence, with level 1 being the lowest and level 5 being the highest, indicating higher levels of independence as the level increases. This study calculates the proportion of individuals with an ADL-MBI score of = 3 at 6 months follow-up. six months
Secondary The modified Rankin Scale (mRS) The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. 30 days
Secondary Hematoma clearance volume The change in hematoma volume compared to the preoperative CT scan was assessed three days postoperatively. 3 days
Secondary Duration of ICU stay Duration of ICU stay six months
Secondary Mean latency of motor-evoked potential (MEP) in upper and lower limbs The motor-evoked potentials in the upper and lower limbs were measured using a direct current cortical stimulator (CCS-1) connected to an electromyograph/evoked potential instrument (NDI-400). The latency data of the motor-evoked potentials were collected, and their average value was calculated. 2 weeks
Secondary adverse events and complications Incidence of adverse events and complications six months
Secondary The number of patients undergoing repeat surgery The number of patients requiring secondary surgery for postoperative complications such as rebleeding, tension pneumocephalus, intracranial infection, and persistent coma assessment. six months
See also
  Status Clinical Trial Phase
Completed NCT04869995 - Behav'Robot: Understanding the Surgeon Behavior During Robot-assisted Surgery
Completed NCT04426500 - Use of Perioperative Pain Blocks In Urological Surgery Phase 3
Completed NCT03636633 - The Effect of Inspiratory Muscle Training and Respiratory Physiotherapy on Pulmonary Functions, Respiratory Muscle Strength and Functional Capacity in Patients With Robotic Heart Surgery N/A
Recruiting NCT04404738 - MicroPort® Endoscopic Instrument Control System to Accomplish Robotic-assisted Surgery in Urology N/A
Recruiting NCT05834569 - Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients Phase 4
Completed NCT02890043 - Clinical Trial for the Application of Tirobot System Phase 3
Completed NCT02665156 - Time Efficiency of Intracorporeal Orthotopic Diversion With Robotic Staplers After Robot Assisted Radical Cystectomy N/A
Recruiting NCT05216276 - Robotic vs. Conventional Minimal-invasive Inguinal Hernia Repair N/A
Not yet recruiting NCT06105203 - RATME vs LATME in Middle and Low Rectal Cancer N/A
Recruiting NCT05600569 - Registry of the Spanish Society of Thoracic Surgery
Completed NCT03111797 - Robot-assisted Lobectomy Versus Video-assisted Lobectomy
Recruiting NCT03280459 - Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction N/A
Completed NCT06317207 - Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy
Completed NCT02360241 - Light Needle Positioning Robot Under MRI Guidance N/A
Recruiting NCT05224895 - The Effect of Trendelenburg Position on the Ultrasonographic Airway Measurements
Recruiting NCT04230772 - Clinical Outcomes of NOSES Versus Traditional Robotic-assisted Surgery for Patients With Colorectal Cancer N/A
Not yet recruiting NCT04235387 - Haemodynamic Changes During Robotic Prostatectomy
Not yet recruiting NCT05642286 - Clinical Study of Endovascular Interventional Surgical Instrument Control System and Related Consumables in Percutaneous Coronary Intervention N/A
Recruiting NCT04440787 - Prevention of Endotracheal Tube Migration by Cuff Palpation During Robotic Surgical Procedure
Not yet recruiting NCT04687384 - Systemic and Peritoneal Inflammatory Response In Robotic-assisted And Laparoscopic Surgery for Colon Cancer N/A